title: National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
authors.affiliation: American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA.
authors.forename: Otis W
authors.initials: OW
authors.lastname: Brawley
authors.forename: Llewellyn J
authors.initials: LJ
authors.lastname: Cornelius
authors.forename: Linda R
authors.initials: LR
authors.lastname: Edwards
authors.forename: Vanessa Northington
authors.initials: VN
authors.lastname: Gamble
authors.forename: Bettye L
authors.initials: BL
authors.lastname: Green
authors.forename: Charles
authors.initials: C
authors.lastname: Inturrisi
authors.forename: Andra H
authors.initials: AH
authors.lastname: James
authors.forename: Danielle
authors.initials: D
authors.lastname: Laraque
authors.forename: Magda
authors.initials: M
authors.lastname: Mendez
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Montoya
authors.forename: Brad H
authors.initials: BH
authors.lastname: Pollock
authors.forename: Lawrence
authors.initials: L
authors.lastname: Robinson
authors.forename: Aaron P
authors.initials: AP
authors.lastname: Scholnik
authors.forename: Melissa
authors.initials: M
authors.lastname: Schori
mesh_terms: D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000986:Antisickling Agents / Q000009:adverse effects / Q000627:therapeutic use*; D035843:Biomedical Research; D002648:Child; D003695:Delivery of Health Care / Q000592:standards; D006297:Health Services Accessibility; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D010146:Pain / Q000517:prevention & control; D010353:Patient Education as Topic / Q000592:standards; D010817:Physician-Patient Relations
chemical_list: D000986:Antisickling Agents; D006918:Hydroxyurea